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Abstract
Cryptogenic stroke is a stroke of unknown aetiology. Over two thirds of cryptogenic strokes have an embolic, mainly cardio-
genic, source. This is why cardiac imaging and looking for cardiac arrhythmia, especially atrial fibrillation, are so important. 
In patients with implanted devices, the routine use of recording intracardiac electrocardiography in the device’s memory 
is recommended in order to find so-called atrial high-rate episodes. The improvements in diagnostic tools and the pro-
gress in atrial fibrillation monitoring have lowered the number of strokes of unknown aetiology, and in many cases have 
allowed the application of appropriate secondary prophylaxis.
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Introduction
Stroke is the third most common cause of death in devel-
oped countries and the leading cause of permanent dis-
ability in adults [1]. The annual incidence in the general 
population is estimated to be 0.2%, which gives a total of 
approximately 15 million patients annually. According to 
the World Health Organisation (WHO) definition, stroke is 
a clinical syndrome consisting of rapidly developing clinical 
signs of focal (or global in the case of coma) disturbance of 
cerebral function lasting more than 24 hours or leading to 
death with no apparent cause other than a vascular origin 
[2]. More than 85% of strokes are ischaemic strokes. The 
current classification of ischaemic stroke with the acronym 
TOAST (Trial of Org 10172 in Acute Stroke Treatment) dis-
tinguishes five subtypes of stroke:
 — large-artery atherosclerosis;
 — cardioembolism;
 — small-vessel occlusion;
 — stroke of other determined aetiology;
 — stroke of undetermined aetiology.
In about 25%, or even as much as 30–40% of cases 
[3], despite extended diagnostics being performed, the 
direct cause of ischaemic stroke remains unknown, and 
such a stroke is referred to as cryptogenic stroke (CS) [4]. 
It is believed that a significant proportion of cryptogenic 
strokes (more than two thirds) are embolic, which is as-
sociated with a much worse prognosis, a higher risk of 
relapse, more severe disability in the future, and higher 
mortality compared to strokes with a different aetiology [5]. 
For this reason, in 2014 the expert group Cryptogenic 
Stroke/ESUS International Working Group introduced the 
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concept of embolic stroke from an undetermined source 
(ESUS) into clinical practice (Table 1) [4].
After the end of treatment of the acute phase of 
an ischaemic stroke, diagnostic steps should be taken 
immediately to determine the most likely cause of it, in-
cluding the exclusion of a cardiogenic embolism. This is 
done by appropriately collected medical history, physical 
examination, preliminary imaging of the brain and cerebral 
vessels [computed tomography (CT), magnetic resonance 
imaging (MRI), Doppler artery], laboratory tests, 12-lead 
electrocardiogram (ECG), or at least 24-hour Holter ECG 
during a patient’s stay in the hospital and transthoracic 
echocardiography (TTE).
The methods of extended cardiac diagnostics, and 
their application in patients after an ischaemic stroke of 
unknown aetiology, ESUS, are presented below.
Electrocardiography, telemetry
A final diagnosis of atrial fibrillation (AF) can be made 
only on the basis of an ECG record. In people with AF, 
arrhythmia may be both symptomatic and asymptomatic 
(so-called ‘silent atrial fibrillation’) [6]. The search for AF 
in a stroke patient should begin as early as during hospi-
talisation. ECG is recommended on admission to hospital, 
but this procedure must not delay the use of appropriate 
treatment. During further observation, continuous heart 
rhythm monitoring should be used for at least 24 hours, 
which exceeds the detectability of AF compared to serially 
performed ECG or 24-hour Holter (4.1–7%) [7]. Studies 
show that diagnostic efficiency increases in proportion 
to the duration of heart rhythm monitoring. On average, 
about 25% of patients after a stroke or transient ischaemic 
attack (TIA) will be diagnosed with AF with long-term heart 
rate monitoring [8]. ECG recording, in addition to the abil-
ity to detect arrhythmias, can also be used to pre-assess 
anatomical changes of the left atrium. There is a proven 
relationship between prolongation of PR interval > 200 ms, 
features of left atrial enlargement (two-phase P wave in 
lead V1, duration of negative phase ≥ 40 ms and ampli-
tude ≥ 0.1 mV), and the occurrence of ischaemic stroke, 
especially embolic types [9]. In 2015, Kamel et al. [10] 
proposed the hypothesis of thrombus formation in the left 
atrium regardless of the presence of AF. The arguments 
presented at the time were based on the results of both 
meta-analyses and randomised clinical trials [AVERROES 
(Apixaban Versus Acetylsalicylic Acid to Prevent Strokes) 
and WARSS, (Warfarin-Aspirin Recurrent Stroke Study)], 
which showed a greater benefit from treatment of respec-
tively apixaban and warfarin than aspirin, as well as the 
lack of an advantage of the rhythm-controlling strategy 
over the strategy of controlling heart rate in people with 
AF in the prevention of ischaemic stroke. This led to the 
concept of so-called atrial cardiopathy, in which not the 
arrhythmia itself is the reason for the formation of thrombi 
and thromboembolic complications, but the unfavourable 
remodelling of the left atrium, with its enlargement, fibro-
sis and abnormal function. ARCADIA (Atrial Cardiopathy 
and Antithrombotic Drugs In Prevention After Cryptogenic 
Stroke) is an ongoing clinical trial that is comparing the 
efficacy of apixaban to that of aspirin in patients with signs 
of atrial cardiopathy and a recent stroke of unknown cause. 
Patients over 45 years of age without known AF will be 
observed for a minimum of 1.5 years and a maximum of 
4 years for subsequent ischaemic strokes and complica-
tions of treatment such as intracranial bleeding or severe 
haemorrhage other than intracranial haemorrhage. ARCA-
DIA has adopted the definition of atrial cardiopathy as the 
presence of PTFV1 (P-wave terminal force) — the product 
of the duration of the negative phase of the P wave and 
its depth in the lead V1 > 0.05 mV × ms, N-terminal pro-
-B-type natriuretic peptide (NT-proBNP) > 250 pg/mL, and 
left atrial dimension index ≥ 3 cm/m2 in echocardiography.
Long-term ECG recording
There are currently many methods available for long-term 
ECG registration. The basic technique is a 24-hour Holter 
test recommended for all patients with a stroke of undeter-
mined cause. Extending the Holter test from 24 hours to 30 
days increases the detection of AF from 4.38% to 15.2%, 
and extended registration up to 180 days gives a possibility 
Table 1. Causes of embolic stroke from an undetermined source 
(ESUS) (based on [4])
Atrium Silent, paroxysmal atrial fibrillation
Atrial high-rate episodes
Atrial asystole and sick-sinus syndrome
Chiari network
Paradoxical  
embolism
Atrial septal aneurysm
Patent foramen ovale 
Mitral valve Myxomatous valvulopathy with prolapse
Mitral annular calcification
Left ventricle Systolic or diastolic dysfunction
Ventricular non-compaction
Endomyocardial fibrosis
Aortic valve, 
aorta
Calcific aortic valve 
Aortic valve stenosis
Aortic arch atherosclerotic plaques
Cancer-associa-
ted
Covert non-bacterial thrombotic endo-
carditis
Tumour emboli from occult cancer
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of detecting arrhythmias in 29.15% of patients [11]. ECG 
registration can also be carried out using the direct data 
transmission method via wireless communication. This 
allows prompt reaction by the centre ordering the exami-
nation and the start of appropriate treatment. In patients 
with symptomatic arrhythmia, Event Holter — a mobile 
telemonitoring device, can be used, in which pressing the 
appropriate button automatically sends an alert to the 
monitoring centre. ECG prolongation should be considered 
especially in patients with risk factors for arrhythmia such 
as hypertension, age ≥ 75 years, valvular heart disease, 
coronary artery disease, peripheral atherosclerosis, obesity, 
and heart failure [12]. In order to better select patients, it is 
also possible to use electrocardiographic and echocardio-
graphic parameters that are associated with the occurrence 
of AF [13, 14] (Table 2).
In the future, telemedicine will greatly facilitate the 
diagnosis of patients with silent AF. There are modern tech-
niques combining standard event loggers with algorithms 
that automatically interpret the heart rhythm and have 
the ability to send data over the telephone network. An 
application for smartphones is available (AliveECG opera-
ting with a special overlay for ECG testing), which has been 
approved for use as a medical product by the US Food and 
Drug Administration (FDA). Thanks to this, you can easily 
carry out an ECG test and send the result to the doctor [15]. 
Implantable loop event recorder
An implantable loop event recorder is a device implanted 
under the skin in the subclavian region which automatically 
records the rhythm of the heart, up to a period of several 
years. The reading is made using an appropriate program-
mer, as well as by communicating with the phone using 
an appropriate application. In the CRYSTAL-AF (Study of 
Continuous Cardiac Monitoring to Assess Atrial Fibrillation 
After Cryptogenic Stroke) clinical trial, in which implantable 
rhythm recorders (ILRs) were used in patients with crypto-
genic stroke, AF was detected in 8.9% of patients after six 
months and in 12.4% after 12 months, compared to 1.4% 
and 2.0% in a control group in which routine 24-hour Holter 
heart rate monitoring was performed [16].
Table 2. Risk factors for atrial fibrillation
Features associated with risk of atrial fibrillation Diagnostic criteria
Electrocardiography (ECG)
PR interval > 200 ms
Features of LA anomalies P wave duration in lead II > 120 ms (often two-hump, the time between two 
peaks ≥ 40 ms) 
or 
in lead V1, two-phase (positive-negative) P waves with negative phase duration 
≥ 40 ms and amplitude ≥ 0.1 mV (1 mm)
Features of left ventricle hypertrophy In patients without intraventricular conduction disturbances (anterior fascicu-
lar block beam, right and left bundle branch block) — at least one of the follo-
wing is sufficient to diagnose left ventricular hypertrophy: R in aVL > 1.1 mV 
(11 mm); R in I + S in III > 2.5 mV (25 mm); R in V5 or V6 > 2.6 mV (26 mm);  
S in V1 + R in V5 or V6 > 3.5 mV (35 mm); S in V2 + R in V5 or V6 > 4.5 mV 
(45 mm); S in V3 + R in aVL > 2.8 mV (28 mm) (men); S in V3 + R in aVL > 2.0 mV 
(20 mm) (women)
Echocardiography
Increased size of left atrium (LA) LA dimension from the back of the aorta to the posterior wall of LA in the para-
sternal long axis at the end-systolic phase
Norm: 3–4 cm in men, 2.7–3.8 cm in women
IVSd Thickness of the ventricular septum in diastole > 1.2 cm
Heart failure with reduced ejection fraction (HFrEF) EF < 40%
Clinical data Age > 75 years
Diabetes
Heart palpitations in the past
Positive family history
Coronary heart disease
LA — left atrium; IVSd — interventricular septal defect; HFrEF — heart failure with reduced ejection fraction; EF — ejection fraction
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a cryptogenic stroke [24], especially in young patients 
where the prevalence is 70–80% [25]. We report the pres-
ence of a PFO if there is a permanent connection between 
the left and right atrium lumen in a place corresponding 
to the location of the foramen ovale. The results of ran-
domised trials [RESPECT (Patent Foramen Ovale Closure 
or Medical Therapy After Stroke), CLOSE (Patent Foramen 
Ovale Closure or Anticoagulants versus Antiplatelet Thera-
py to Prevent Stroke Recurrence), REDUCE (GORE® Septal 
Occluder Device for Patent Foramen Ovale (PFO) Closure 
in Stroke Patients)] for secondary stroke prophylaxis in 
patients with PFO comparing pharmacological treatment 
and percutaneous surgical techniques to closing the oval 
opening indicate the benefits of invasive treatment in 
reducing the risk of recurrent ischaemic stroke. A PFO is 
difficult to identify in a transthoracic study due to its small 
size, thin primary septum at the level of the foramen ovale, 
and the position at the back of the heart which is asso-
ciated with a greater distance from the chest wall. The gold 
standard for PFO diagnostics is TEE using a contrast agent 
and a correctly performed Valsalva manoeuvre. However, 
TEE is not required if there is good image quality in the 
TTE [26]. As a contrast agent, about 8 mL of heparinised 
saline and 1 mL of air are used [27]. The first application 
of the contrast should be made during steady breathing, 
because a small left-right leak may persist in a chronic 
elevation in the right atrium pressure. Subsequent ad-
ministration takes place during the patient’s Valsalva 
manoeuvre, which temporarily increases the pressure in 
the right atrium. The risk of stroke in patients with PFO is 
thought to increase with an increasing size of leak [28], 
something which can be assessed in two ways: either by 
counting the number of air bubbles in the left atrium dur-
ing the first three heart contractions after the right atrium 
is completely filled with contrast agent, or by making 
a morphological description in the TEE which determines 
the degree of separation of the primary and secondary 
plaque and the size of the foramen ovale. However, there 
is a lack of a standardised projection in which this assess-
ment should be made. To make a therapeutic decision, it 
Implantable devices
Stimulators of the heart such as implantable cardioverter-
-defibrillator and cardiac resynchronisation therapy have 
the ability to record the patient’s own rhythm in a given 
time interval alongside their basic functions, thanks to 
the presence of intracardiac electrodes. There is a rela-
tionship between the occurrence of rapid atrial rhythms 
(AHRE) and the risk of ischaemic stroke, which is nearly 
2.5 times higher in this group of patients [17]. AHRE is 
defined as atrial episodes with a frequency > 190/min 
lasting > 6 minutes detected by a two-chamber implan-
table device. Although an association between AHRE and 
stroke has been proven, the question of the total duration 
of AHRE found in the device control which would clearly 
indicate the need to include oral anticoagulation remains 
unanswered. This time should be 5.5–6 hours according 
to some authors [18], and even > 24 hours according to 
others [19]. Therefore, due to the lack of clear guidelines, 
decisions regarding anticoagulant therapy in this group of 
patients are still made individually.
Echocardiography
The ‘gold standard’ in the search for cardiogenic causes 
of embolic stroke is transthoracic echocardiography (TTE). 
According to the 2018 guidelines for the management of 
ischaemic stroke it is not recommended to perform TTE 
routinely, but it may be considered in special cases such 
as cryptogenic stroke [20]. This is a widely available, cheap 
and safe study, with the help of which we can recognise 
the majority of potential sources of thrombus formation for 
which there are specific treatment methods and secondary 
prophylaxis of stroke.
Transoesophageal echocardiography
Transoesophageal echocardiography (TEE) is a more sens-
itive test to detect potential embolus sources because it 
allows for a more accurate depiction of the left atrium, 
aortic arch, abnormal intracardiac structures, and leaks 
(Table 3) [21, 22]. The disadvantage of TEE is its invasive 
nature and potential complications such as hoarseness, 
dysphagia, odynophagia, and damage to mucous membra-
nes, teeth, oesophagus, and vocal cords as well as brady-
cardia [23]. Despite the high sensitivity of TEE, the presence 
of thrombus, spontaneous echocardiographic contrast or 
cardiac tumours is found in less than 1% of patients with 
ESUS. The most frequently detected potential sources of 
an embolism in TEE are aortic laminae and intracardiac 
leaks, mainly through the patent foramen ovale and defects 
of the atrial septum.
The results of many studies have shown a much higher 
occurrence of patent foramen ovale (PFO) in patients with 
Table 3. Two-dimensional (2D) accuracy of transthoracic and 
transoesophageal echocardiography in selected clinical situ-
ations (based on [22])
Clinical situation 2D TTE 2D TEE
Infective endocarditis ++ +++
Tumours inside heart ++ +++
Thrombus in left ventricle +++ +
Thrombosis on artificial valve + +++
Atherosclerotic plaque in aorta + +++
Patent foramen ovale + +++
Precision: + low, ++ average, +++ high
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is also necessary to assess the presence of anatomical 
risk factors such as resting right-left leak, large PFO > 
> 4 mm, large leak (> 20 bubbles in TEE), large Eustachian 
valve > 10 mm, Chiari network, long PFO channel, and the 
presence of an atrial septal aneurysm.
An isolated atrial septal aneurysm (ASA) occurs in 
2–3% of the population, and in 20% of cases it coexists 
with a PFO. It is believed that in people < 55 years, the 
risk of stroke increases in the presence of isolated ASA 
[odds ratio (OR) 6.1], PFO (OR 3.1) and is highest with the 
coexistence of PFO and ASA (OR 15.5) [29]. Diagnosis is 
made on the basis of the assessment of the atrial septum 
in a TTE or TEE study. The exact criteria are not precisely 
determined, but it is assumed that the width of the base 
of the aneurysm should be 10–15 mm, with an inclination 
towards the left or right atrium of at least 10 mm. A special 
RoPE (Risk of Paradoxical Embolism) scoring scale has 
been created to assess the likelihood of a cryptogenic 
stroke in patients with PFO (Table 4) [30, 31]. A total score 
> 6 points indicates a high risk of stroke in the mechanism 
of a paradoxical embolism.
Magnetic resonance
An alternative non-invasive diagnostic method for TEE may 
be cardiac magnetic resonance imaging (CMRI). CMRI 
is ideal for the evaluation of left ventricular mass and 
left atrial volume and for the differentiation of thrombus 
with abnormal structures in the heart cavities, such as 
myxomas. When performing a contrast study, areas of 
scarring or fibrosis in the myocardium may be identified, 
and the addition of phase contrast may identify a leak in 
the heart, such as an atrial septal defect [32]. CMRI is 
a good method for imaging tumours and cardiomyopathy, 
as well as the aortic arch. Information on the use of 
CMRI in the diagnosis of cryptogenic stroke is negligible. 
Although there is data regarding a larger percentage 
of the diagnosis of the cause of ESUS, there has been 
insufficient research into the possibility of using it as an 
alternative to TEE [33].
Conclusions
Cardiac assessment is an indispensable element of patient 
management following a stroke. Each patient in a Stroke 
Unit should have an electrocardiographic examination 
performed in addition to a detailed interview, physical exa-
mination, and brain imaging study to confirm the diagnosis. 
In selected cases, especially among patients with structu-
ral heart disease or in patients < 45 years of age, easily 
available and non-invasive transthoracic echocardiography 
should be considered.
However, for the majority of patients, a transoesopha-
geal examination is necessary to detect the embolic source 
because TEE is characterised by a higher sensitivity and 
higher specificity than TTE [34]. The concept of atrial car-
diopathy seems to be attractive, but it requires validation 
from ongoing randomised clinical trials. The diagnosis 
and documentation of silent AF remain a major diagnostic 
challenge. In the case of stroke of unknown aetiology, it is 
reasonable to prolong the monitoring of cardiac function 
up to 30 days or even longer by means of Holter recording 
or an implantable event recorder. The choice of appropriate 
method depends on the patient’s preferences as well as 
on the availability of diagnostic methods in a given centre. 
There are many ways, both pharmacological and surgical, 
to prevent incidences of recurrent stroke, which is why it is 
so important to determine its aetiology as early as possible 
and to apply appropriate secondary prophylaxis.
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Table 4. Risk calculator of paradoxical embolism among patients 
with embolic stroke from an undetermined source and patent 
foramen ovale [RoPE (Risk of Paradoxical Embolism)] (based on 
[30])
Risk factors Points
Lack of history of hypertension 1
Lack of history of diabetes 1
Lack of history of stroke/transient ischaemic 
attack
1
Lack of history of smoking 1
Cortical infarct on imaging 1
Age [years]:
• 18–29 5
• 30–39 4
• 40–49 3
• 50–59 2
• 60–69 1
• ≥ 70 0
361www.journals.viamedica.pl/folia_cardiologica
Elwira Bakuła-Ostalska, Janusz Bednarski, Cryptogenic stroke: cardiac diagnostics
Streszczenie
Udar kryptogenny to udar mózgu o nieznanej etiologii. Ponad 2/3 udarów kryptogennych ma podłoże zatorowe, głów-
nie kardiogenne. Dlatego tak ważne są obrazowa diagnostyka kardiologiczna oraz diagnostyka zaburzeń rytmu serca, 
zwłaszcza migotania przedsionków.
U osób z implantowanymi urządzeniami wszczepialnymi należy rutynowo wykorzystywać zapisy wewnątrzsercowego elek-
trokardiogramu w pamięci urządzenia, w poszukiwaniu tak zwanych szybkich rytmów przedsionkowych. Udoskonalenie 
narzędzi diagnostycznych oraz postępy w wykrywaniu migotania przedsionków sprawiają, że coraz mniej udarów mózgu 
pozostaje bez ustalonej przyczyny, co w wielu przypadkach pozwala na odpowiednio wczesne wdrożenie profilaktyki 
wtórnej.
Słowa kluczowe: udar kryptogenny, udar zatorowy z nieokreślonego źródła, diagnostyka kardiologiczna, przetrwały 
otwór owalny, migotanie przedsionków
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